Association of PSA Decline With Clinical Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving Apalutamide Plus ADT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
Ann. Oncol 2023 Feb 27;[EPub Ahead of Print], S Chowdhury, A Bjartell, N Agarwal, BH Chung, RW Given, AJ Pereira de Santana Gomes, AS Merseburger, M Özgüroğlu, ÁJ Soto, H Uemura, D Ye, SD Brookman-May, A Londhe, A Bhaumik, SD Mundle, JS Larsen, SA McCarthy, KN ChiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.